Under COMPETE P2030, AccelBio has secured approval for Bio-Transfer: Biomedical Knowledge Commercialization Program, a joint initiative led by i3S, AccelBio, and CoLAB Trials.
Bio-Transfer aims to strengthen biomedical technology transfer and commercialisation through an integrated national framework and five interconnected actions, including:
The programme will also track the progress of supported startups and consolidate learnings into a community-facing white paper.